177Lu radiolabeled peptides for breast cancer therapy [abstract]
No Thumbnail Available
Sponsors
Date
Journal Title
Format
Abstract
Abstract
ErbB-2 is a type 1 receptor tyrosine kinase over-expressed on ~30% of breast cancers and is an attractive target for the development of new diagnostic and therapeutic agents. The ErbB-2 avid peptide KCCYSL, originally identified from phage display, has shown promising imaging results in pre-clincial breast carcinoma animal models. In this study the peptide DOTA-GSGKCCYSL was radiolabeled with the beta-particle emitter lutetium-177 (177Lu) and examined for its therapeutic potential. The peptide DOTA-GSG-KCCYSL was synthesized using Fmoc solid phase peptide synthesis and purified to homogeneity. DOTA-GSG-KCCYSL was radiolabeled with Lu-177 and purified via high performance liquid chromatography. In vitro stability studies showed that the radiolabeled complex was stable to challenges from metal chelators and was stable to >60% in serum at 37[degrees]C over 24 h. Cell binding of 177Lu-DOTA-GSG-KCCYSL to MB- 435 human breast carcinoma cells displayed saturable binding at 2 h. Log P studies indicated that the radiolabeled complex was very hydrophilic. Initial biodistribution studies in MB-435 xenografted mice showed modest tumor uptake of 1.82 % injected dose per gram (ID/g) 30 min post injection and 0.56 % ID/g at 1 h post injection. Additional biodistribution and imaging studies are underway to determine dosimetry and potential tumor therapeutic properties.
Table of Contents
DOI
PubMed ID
Degree
Thesis Department
Rights
OpenAccess.
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License.